Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.

about

IL-10/STAT3 is reduced in childhood obesity with hypertriglyceridemia and is related to triglyceride level in diet-induced obese rats.

P2860

Q55285673-2DC78B50-B92A-4A5B-ACC9-43313B6375BC

P2860

Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.

Item

http://www.wikidata.org/entity/Q38675599

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Growth hormone prescribing and ...... out additional gain in height.

@en

type

Item

label

Growth hormone prescribing and ...... out additional gain in height.

@en

prefLabel

Growth hormone prescribing and ...... out additional gain in height.

@en

P1476

Growth hormone prescribing and ...... out additional gain in height.

@en

P2093

Anne Povall

http://www.w3.org/2001/XMLSchema#string

Jennifer Bellis

http://www.w3.org/2001/XMLSchema#string

Jo Blair

http://www.w3.org/2001/XMLSchema#string

Matthew Peak

http://www.w3.org/2001/XMLSchema#string

Paul Newland

http://www.w3.org/2001/XMLSchema#string

Paul Richardson

http://www.w3.org/2001/XMLSchema#string

Victoria Price

http://www.w3.org/2001/XMLSchema#string

P2860

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

Growth hormone binding protein - physiological and analytical aspects

Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010

Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS).

Contributions of incidence and persistence to the prevalence of childhood obesity during the emerging epidemic in Denmark

The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects.

Development of a WHO growth reference for school-aged children and adolescents

Effect of obesity on the pharmacokinetics of drugs in humans.

Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence.

P304

e0181567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0181567

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel B. Hawcutt

P577

2017-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28715498

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

P932

5513545

http://www.w3.org/2001/XMLSchema#string

Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.

about

P2860

P2860

Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932